Abstract:Innate immune response provides the host with an early protection barrier against invading pathogens and helps shape the nature and quality of the subsequent adaptive immune response of the host. Ubiquitin-specific protease 18 (USP18 ) plays an important role in the host innate immune response. This role is mediated both via its enzymatic and non-enzymatic functions. First, conjugation of ISG15 to its targets is counteracted by the enzymatic activity of USP18. Second, the C terminus of USP18 can bind to the type I interferon receptor subunit (IFNAR2) and compete with JAK1 receptor binding which inhibits the activation of the receptor associated kinases JAK1 and TYK2. While USP18 deficiency prolonged phosphorylation of STATs and increased ISG expression in response to IFN, forced expression of either wild type or enzymatically inactive mutatant USP18 in the cells reduces the phosphorylation level of STATs and the downstream transcriptional events. USP18 knockout mice have a greater resistance to viral/bacterial infection in several experimental mouse models. In addition, USP18 was found to inhibit IFNsignaling but did not inhibit IFN, IFN, IL-6, or IL-12 signaling pathways. Results from our previous study demonstrated that USP18 was overexpressed in the liver biopsy specimens of HCV patients who do not respond to the combination therapy of pegylated interferon-alpha (IFN) and ribavirin (RBV). We also found that increased expression of either wild type USP18 or catalytically inactive mutant USP18 blunted the effect of both type I and type III IFNs and promoteded HCV production in the J6/JFH1 culture system. Another study suggested that HBV infection is more rapidly cleared if USP18 expression level is reduced. Most recently it has been shown that USP18 may play an important role in mediating inflammation. Inhibition of USP18 leads to upregulation of several pro-inflammatory chemokine, including CCL5, CXCL10 and IL-15, via induction of the STAT signaling pathway and increases IFN induced beta cell apoptosis. Taken together, small molecule inhibitors against USP18 might be a viable approach to potentiate the host innate immunity leading to a better control of viral infections.

USP39 Serves as a Deubiquitinase to Stabilize STAT1 and Sustains Type I IFN–Induced Antiviral Immunity

Deubiquitinase USP2a Sustains Interferons Antiviral Activity by Restricting Ubiquitination of Activated STAT1 in the Nucleus

Ubiquitin-Specific Protease 13 Regulates IFN Signaling by Stabilizing STAT1

Methyltransferase SETD2-Mediated Methylation of STAT1 is Critical for Interferon Antiviral Activity.

Deubiquitinase USP47 attenuates virus-induced type I interferon signaling

USP49 Potently Stabilizes APOBEC3G Protein by Removing Ubiquitin and Inhibits HIV-1 Replication

Usp19 Modulates Autophagy and Antiviral Immune Responses by Deubiquitinating Beclin-1

USP7-TRIM27 Axis Negatively Modulates Antiviral Type I IFN Signaling.

USP38 Inhibits Type I Interferon Signaling by Editing TBK1 Ubiquitination Through NLRP4 Signalosome.

USP21 Negatively Regulates Antiviral Response by Acting As a RIG-I Deubiquitinase

SIAH1 modulates antiviral immune responses by targeting deubiquitinase USP19

The role of USP 18 in interferon signaling and inflammation

USP44 positively regulates innate immune response to DNA viruses through deubiquitinating MITA

USP3 Inhibits Type I Interferon Signaling by Deubiquitinating RIG-I-like Receptors

USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma

Deacetylase Sirtuin 1 mitigates type I IFN- and type II IFN-induced signaling and antiviral immunity

USP13 negatively regulates antiviral responses by deubiquitinating STING

USP49 negatively regulates cellular antiviral responses via deconjugating K63-linked ubiquitination of MITA

USP26 suppresses type I interferon signaling by targeting TRAF3 for deubiquitination

USP20 Promotes Cellular Antiviral Responses via Deconjugating K48-Linked Ubiquitination of MITA

A co-opted ISG15-USP18 binding mechanism normally reserved for deISGylation controls type I IFN signalling